Changing the standard of care in 2nd line recurrent cervical cancer

Video Transcription

Video Summary

In this webinar, Dr. Brian Slomovitz discusses the results of the Innovative 301 trial, a phase 3 study evaluating the use of tezotamab vidotin (TV) in the second or third-line management of recurrent or metastatic cervical cancer. The trial showed that TV demonstrated a statistically significant and clinically meaningful improvement in overall survival, with a 30% reduction in the risk of death compared to investigative choice chemotherapy. The median overall survival in the TV arm was 11.5 months compared to 9.5 months in the chemotherapy arm. Progression-free survival was also improved with TV, with a 33% decrease in the risk of recurrence or death. TV was generally well-tolerated, with manageable side effects. The study concluded that TV should be considered as a potential new standard of care for patients with recurrent or metastatic cervical cancer who have progressed after first-line systemic therapy.

Keywords

webinar

Dr. Brian Slomovitz

tezotamab vidotin

cervical cancer

overall survival

progression-free survival